Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith B Elkon

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 24, 2011
Type I interferon and systemic lupus erythematosusKeith B Elkon, Vivian V Stone
Rheumatic Diseases Clinics of North America|July 21, 2004
Mechanisms of apoptosisDavid A Martin, Keith B Elkon
The Journal of Experimental Medicine|December 7, 2005
Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificityDavid A Martin, Keith B Elkon
Nature Reviews. Rheumatology|July 26, 2020
The (Orf)ull truth about IRF5 and type I interferons in SLEKeith B Elkon, Tracy A Briggs
Current Directions in Autoimmunity|January 6, 2006
Role of complement and other innate immune mechanisms in the removal of apoptotic cellsCarol Anne Ogden, Keith B Elkon
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Reply: To PMID 23840006Alice E Wiedeman, Keith B Elkon
Critical Reviews in Immunology|January 17, 2008
Peripheral CD8 T-cell responses to apoptotic cell proteins and peptidesYu Feng Peng, Keith B Elkon
Current Opinion in Immunology|September 25, 2012
Complement, interferon and lupusKeith B Elkon, Deanna M Santer
Arthritis and Rheumatism|February 5, 2005
Single-dose therapy for lupus nephritis: C-reactive protein, nature's own dual scavenger and immunosuppressantCarol Anne Ogden, Keith B Elkon
Arthritis and Rheumatism|March 2, 2006
Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathwayDavid A Martin, Keith B Elkon
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 24, 2011
Type I interferon and systemic lupus erythematosusKeith B Elkon, Vivian V Stone
Rheumatic Diseases Clinics of North America|July 21, 2004
Mechanisms of apoptosisDavid A Martin, Keith B Elkon
The Journal of Experimental Medicine|December 7, 2005
Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificityDavid A Martin, Keith B Elkon
Nature Reviews. Rheumatology|July 26, 2020
The (Orf)ull truth about IRF5 and type I interferons in SLEKeith B Elkon, Tracy A Briggs
Current Directions in Autoimmunity|January 6, 2006
Role of complement and other innate immune mechanisms in the removal of apoptotic cellsCarol Anne Ogden, Keith B Elkon
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Reply: To PMID 23840006Alice E Wiedeman, Keith B Elkon
Critical Reviews in Immunology|January 17, 2008
Peripheral CD8 T-cell responses to apoptotic cell proteins and peptidesYu Feng Peng, Keith B Elkon
Current Opinion in Immunology|September 25, 2012
Complement, interferon and lupusKeith B Elkon, Deanna M Santer
Arthritis and Rheumatism|February 5, 2005
Single-dose therapy for lupus nephritis: C-reactive protein, nature's own dual scavenger and immunosuppressantCarol Anne Ogden, Keith B Elkon
Arthritis and Rheumatism|March 2, 2006
Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathwayDavid A Martin, Keith B Elkon
Pageof 9